| Mosunetuzumab studied in …STUDIED_INderived50 of 50show fewer |
|---|
| → studied in | NCT06284122Phase 3 · active not recruiting Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06337318Phase 3 · recruiting Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma · 50 trials list this drug (42 active) | — | — | Classic Follicular Lymphoma,Follicular Lymphoma with Unusual Cytological Features | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07548450Phase 2 · not yet recruiting Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) · 50 trials list this drug (42 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · 50 trials list this drug (42 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma,Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615636Phase 2 · recruiting A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL · 50 trials list this drug (42 active) | — | — | B-Cell Malignant Neoplasm,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04246086Phase 1/Phase 2 · active not recruiting A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04889716Phase 2 · active not recruiting CAR-T Followed by Bispecific Antibodies · 50 trials list this drug (42 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06090539Phase 1/Phase 2 · recruiting A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas · 50 trials list this drug (42 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06634589Phase 1/Phase 2 · recruiting A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies · 50 trials list this drug (42 active) | — | — | Malignant Neoplasm,B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05091424Phase 1 · recruiting A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia · 50 trials list this drug (42 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05207670Phase 2 · active not recruiting A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies · 50 trials list this drug (42 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05886036Phase 2 · recruiting Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial · 50 trials list this drug (42 active) | — | — | Nodular Lymphocyte Predominant B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06442475Phase 2 · recruiting Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · 50 trials list this drug (42 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma,Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06594939Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma · 50 trials list this drug (42 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792502Phase 2 · recruiting Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma · 50 trials list this drug (42 active) | — | — | B-Cell Malignant Neoplasm,Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169515Phase 1 · active not recruiting A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma · 50 trials list this drug (42 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07566364Phase 2 · recruiting Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD · 50 trials list this drug (42 active) | — | — | Lymphoid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389293Phase 2 · recruiting A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma · 50 trials list this drug (42 active) | — | — | Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05171647Phase 3 · active not recruiting A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma · 50 trials list this drug (42 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563505Phase 2 · recruiting A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma · 50 trials list this drug (42 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04970901Phase 1 · active not recruiting A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) · 50 trials list this drug (42 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638722Phase 2 · not yet recruiting Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment · 50 trials list this drug (42 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Splenic Marginal Zone Lymphoma,Nodal Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04712097Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672251Phase 2 · recruiting Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 50 trials list this drug (42 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06015880Phase 1 · recruiting Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 50 trials list this drug (42 active) | — | — | Diffuse Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06249191Phase 1/Phase 2 · recruiting Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma · 50 trials list this drug (42 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06006117Phase 3 · recruiting Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma · 50 trials list this drug (42 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07555470Phase 2 · recruiting Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948786Phase 2 · recruiting Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma,Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05412290Phase 1 · active not recruiting Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma · 50 trials list this drug (42 active) | — | — | B-Cell Malignant Neoplasm,Transformed Non-Hodgkin Lymphoma,Aggressive Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169658Phase 2 · completed Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma · 50 trials list this drug (42 active) | — | — | Non-Hodgkin Lymphoma,Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Indolent B-Cell Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05994235Phase 2 · active not recruiting Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07278921recruiting Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP). · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633615Phase 2 · recruiting Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · 50 trials list this drug (42 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05464329Phase 1 · active not recruiting Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma · 50 trials list this drug (42 active) | — | — | Grade 3b Follicular Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05260957Phase 2 · recruiting CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). · 50 trials list this drug (42 active) | — | — | Non-Hodgkin Lymphoma,Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05410418Phase 2 · active not recruiting Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07052695Phase 1/Phase 2 · recruiting Mosunetuzumab for CLL MRD Clearance · 50 trials list this drug (42 active) | — | — | Leukemia,Lymphoma,Chronic Lymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06569680Phase 2 · recruiting Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma · 50 trials list this drug (42 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06828991Phase 2 · recruiting A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP · 50 trials list this drug (42 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02500407Phase 1/Phase 2 · completed A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) · 50 trials list this drug (42 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03677154Phase 1/Phase 2 · completed Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma · 50 trials list this drug (42 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07031700Phase 2 · not yet recruiting A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03677141Phase 1/Phase 2 · completed A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma · 50 trials list this drug (42 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03671018Phase 1/Phase 2 · active not recruiting A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma · 50 trials list this drug (42 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05315713Phase 1/Phase 2 · terminated An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma · 50 trials list this drug (42 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04313608Phase 1 · completed A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma · 50 trials list this drug (42 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05849857Phase 2 · recruiting Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries · 50 trials list this drug (42 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05961696Phase 1 · withdrawn A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia · 50 trials list this drug (42 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05205252Phase 1/Phase 2 · withdrawn A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. · 50 trials list this drug (42 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |